Generic name: fremanezumab |
||
---|---|---|
Strength & form |
225 mg in 1.5 mL (150 mg/mL) solution for subcutaneous injection |
Special Authority criteria |
Approval period |
---|---|
Initial
AND
AND
|
6 months |
First renewal The patient has had a minimum reduction of at least 50% in the average number of migraine days per month2 compared to baseline |
6 months |
Second and subsequent renewals The patient has maintained a minimum reduction of at least 50% in the average number of migraine days per month2 compared to baseline |
1 year |
Anti-seizure medications:
|
Serotonin and norepinephrine reuptake inhibitors:
|
Beta-blockers:
|
Tricyclic antidepressants:
|
Calcium channel blockers:
|
Renin-angiotensin-aldosterone system inhibitors:
|
Miscellaneous:
|